Uri Lopatin

2.8k total citations · 1 hit paper
32 papers, 2.0k citations indexed

About

Uri Lopatin is a scholar working on Epidemiology, Hepatology and Immunology. According to data from OpenAlex, Uri Lopatin has authored 32 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 19 papers in Hepatology and 9 papers in Immunology. Recurrent topics in Uri Lopatin's work include Hepatitis B Virus Studies (18 papers), Hepatitis C virus research (18 papers) and Liver Disease Diagnosis and Treatment (8 papers). Uri Lopatin is often cited by papers focused on Hepatitis B Virus Studies (18 papers), Hepatitis C virus research (18 papers) and Liver Disease Diagnosis and Treatment (8 papers). Uri Lopatin collaborates with scholars based in United States, Italy and New Zealand. Uri Lopatin's co-authors include John S. Francis, Meg Doherty, David L. Thomas, Eric L. Nuermberger, Nadia N. Hansel, John R. Ticehurst, John G. Bartlett, Mian Cai, Trish M. Perl and Tracy Ross and has published in prestigious journals such as The Lancet, Blood and Gastroenterology.

In The Last Decade

Uri Lopatin

32 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Severe Community-Onset Pneumonia in Healthy Adults Caused by Methicillin-Resistant Staphylococcus aureus Carrying the Panton-Valentine Leukocidin Genes

2004 560 citations John S. Francis, Meg Doherty et al. Clinical Infectious Diseases profile →

Peers

Countries citing papers authored by Uri Lopatin

Since Specialization

Citations

This map shows the geographic impact of Uri Lopatin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uri Lopatin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uri Lopatin more than expected).

Fields of papers citing papers by Uri Lopatin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uri Lopatin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uri Lopatin. The network helps show where Uri Lopatin may publish in the future.

Co-authorship network of co-authors of Uri Lopatin

This figure shows the co-authorship network connecting the top 25 collaborators of Uri Lopatin. A scholar is included among the top collaborators of Uri Lopatin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uri Lopatin. Uri Lopatin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of in vitro antiviral activity of SARS-CoV-2 M ^pro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions 2023 ·Antimicrobial Agents and Chemotherapy ·(unknown), (unknown), Lee D. Arnold, Laura J. Stevens, Andrea J. Pruijssers, Seunghyi Kook, Uri Lopatin, Mark R. Denison, Ann D. Kwong	17
2	Drugs in the Pipeline for HBV 2019 ·Clinics in Liver Disease ·Uri Lopatin	44
3	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial 2019 ·The Lancet. Gastroenterology & hepatology ·Man‐Fung Yuen, Kosh Agarwal, Edward Gane, Christian Schwabe, Sang Hoon Ahn, Dong Joon Kim, Young‐Suk Lim, Wendy Cheng, William Sievert, Kumar Visvanathan, Eric Ruby, (unknown), Ran Yan, (unknown), Richard J. Colonno, Uri Lopatin	81
4	Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients 2017 ·Antiviral Research ·Louis Jansen, Matthijs R. A. Welkers, Karel A. van Dort, R. Bart Takkenberg, Uri Lopatin, Hans L. Zaaijer, Menno D. de Jong, Hendrik W. Reesink, Neeltje A. Kootstra	11
5	P0529 : Anti capsid drugs HAP12 and AT130 target HBV core protein nuclear functions 2015 ·Journal of Hepatology ·Laura Belloni, (unknown), (unknown), Lin Li, Srinivas Reddy Chirapu, (unknown), M. G. Finn, Uri Lopatin, Adam Zlotnick, Massimo Levrero	5
6	HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels 2014 ·Journal of Hepatology ·Louis Jansen, A. de Niet, F. Stelma, Erik P.A. van Iperen, Karel A. van Dort, (unknown), R. Bart Takkenberg, Daniel J. Chin, A. H. Zwinderman, Uri Lopatin, Neeltje A. Kootstra, Hendrik W. Reesink	16
7	Reduction of HBV replication prolongs the early immunological response to IFNα therapy 2013 ·Journal of Hepatology ·Anthony T. Tan, Long Hoàng, Daniel J. Chin, Erik Rasmussen, Uri Lopatin, Stefan Hart, Hans Bitter, Tom Chu, Lore Gruenbaum, (unknown), Hua Zhong, Ed Gane, Seng Gee Lim, Wan Cheng Chow, Pei‐Jer Chen, Rosemary Petric, Antonio Bertoletti, Martin L. Hibberd	62
8	Transcriptomic analysis of the woodchuck model of chronic hepatitis B 2012 ·Hepatology ·Simon P. Fletcher, Daniel J. Chin, Yongmei Ji, Leonardo Iniguez, Bruce E. Taillon, David C. Swinney, Palanikumar Ravindran, Donavan T. Cheng, Hans Bitter, Uri Lopatin, Han Ma, Klaus Klumpp, Stephan Menne	78
9	Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C 2012 ·Gastroenterology ·Tom Chu, Rohit Kulkarni, Edward Gane, Stuart K. Roberts, Catherine Stedman, Peter Angus, Brett Ritchie, (unknown), David Ipe, Uri Lopatin, Søren Germer, Victor A. Iglesias, Robert C. Elston, Patrick F. Smith, Nancy S. Shulman	72
10	Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir 2012 ·Scandinavian Journal of Gastroenterology ·A. de Niet, R. Bart Takkenberg, Ryma Benayed, Bridget Riley‐Gillis, Christine J. Weegink, Hans L. Zaaijer, M. Koot, P. L. M. Jansen, Marcel Beld, Uri Lopatin, Hendrik W. Reesink	29
11	739 EFFECTS OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN CHRONIC HBV PATIENTS IN THREE GLOBAL RANDOMIZED STUDIES 2011 ·Journal of Hepatology ·Patrick Marcellin, E.J. Heathcote, Thomas Berg, Jane Anderson, Elsa Mondou, (unknown), Ramin Ebrahimi, Sudheer C. Reddy, Uri Lopatin, J. McNally, (unknown)	6
12	737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS 2011 ·Journal of Hepatology ·Uri Lopatin, Grushenka H.I. Wolfgang, (unknown), (unknown), (unknown), Gregory E. Chittick, Christian Frey, John W. A. Findlay, (unknown), Brian P. Kearney, Chris Barnes, John McHutchinson, Kenneth Hirsch	6
13	Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial 2010 ·The Lancet ·Edward Gane, Stuart K. Roberts, (unknown), Peter Angus, Brett Ritchie, Rob Elston, David Ipe, Peter N. Morcos, Linda Baher, Isabel Nájera, Tom Chu, Uri Lopatin, M. Michelle Berrey, William Bradford, Mark Laughlin, Nancy S. Shulman, Patrick F. Smith	240
14	1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN 2010 ·Journal of Hepatology ·Tarik Asselah, Laurent Essioux, Patrick Marcellin, (unknown), Dorte Møller Jensen, Søren Germer, Ryma Benayed, Tom Chu, Andreas Tietz, D P Chin, Nancy S. Shulman, James Thommes, Mark Laughlin, Uri Lopatin	14
15	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression 2009 ·Clinical Gastroenterology and Hepatology ·Tara N. Palmore, Neeral L. Shah, Rohit Loomba, Brian B. Borg, Uri Lopatin, Jordan J. Feld, (unknown), Glen Lutchman, David E. Kleiner, Neal S. Young, Richard Childs, A. John Barrett, T. Jake Liang, Jay H. Hoofnagle, Theo Heller	57
16	Actinomyces in Chronic Granulomatous Disease: An Emerging and Unanticipated Pathogen 2009 ·Clinical Infectious Diseases ·Janine Reichenbach, Uri Lopatin, Nizar Mahlaoui, Bojana Beovič, Ulrich Siler, Reinhard Zbinden, Reinhard Seger, Louise Galmiche, Nicole Brousse, Samer Kayal, Tayfun Güngör, Stéphane Blanche, Steven M. Holland	46
17	Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance 2008 ·Current Opinion in Immunology ·María Rescigno, Uri Lopatin, Marcello Chieppa	80
18	Severe Community-Onset Pneumonia in Healthy Adults Caused by Methicillin-Resistant Staphylococcus aureus Carrying the Panton-Valentine Leukocidin Genes breakdown → 2004 ·Clinical Infectious Diseases ·John S. Francis, Meg Doherty, Uri Lopatin, (unknown), Gita Sinha, Tracy Ross, Mian Cai, Nadia N. Hansel, Trish M. Perl, John R. Ticehurst, Karen C. Carroll, David L. Thomas, Eric L. Nuermberger, John G. Bartlett	560
19	Characterization of a Mycobacterium smegmatis Mutant That Is Simultaneously Resistant to d -Cycloserine and Vancomycin 2000 ·Antimicrobial Agents and Chemotherapy ·(unknown), Anatoly Severin, Frances Zhao, Dalya R. Soond, Uri Lopatin, (unknown), Aimee E. Belanger, Bohdan P. Harvey, Graham F. Hatfull, Patrick J. Brennan, Nancy Connell	11
20	Autoimmune Lymphoproliferative Syndrome: A Syndrome Associated with Inherited Genetic Defects That Impair Lymphocytic Apoptosis—CT and US Features 1999 ·Radiology ·Nilo A. Avila, Andrew J. Dwyer, Janet K. Dale, Uri Lopatin, Michael C. Sneller, Elaine S. Jaffe, Jennifer M. Puck, Stephen E. Straus	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact